Table 1
Chemotherapy in addition to supportive care in advanced NSCLC: main results of the meta-analysis performed on individual patient data from 16 randomised controlled trials [
2
]
Arm
Chemotherapy
Supportive care
Patients n
1399
1315
Deaths n
1293
1240
Hazard ratio
0.77
95% CI : 0.71–0.83 P<0.0001
1-yr survival
29%
20%
Median survival
6 months
4.5 months